{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T16:05:51Z","timestamp":1780934751821,"version":"3.54.1"},"update-to":[{"DOI":"10.1002\/14651858.cd011655","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,3,25]],"date-time":"2017-03-25T00:00:00Z","timestamp":1490400000000}}],"reference-count":59,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011655.pub2","type":"journal-article","created":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T03:32:20Z","timestamp":1490671940000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Chlorpromazine versus metiapine for schizophrenia"],"prefix":"10.1002","volume":"2017","author":[{"given":"Morteza","family":"Zare","sequence":"first","affiliation":[{"name":"Shiraz University of Medical Sciences; Nutrition Research Center, School of Nutrition and Food Sciences; Shiraz Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azam","family":"Bazrafshan","sequence":"additional","affiliation":[{"name":"Kerman University of Medical Sciences; Neuroscience Research Center, Institute of Neuropharmacology; Kerman Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,3,25]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD011655.pub2-BIB0001|cit1","first-page":"839","article-title":"A double-blind evaluation of metiapine in hospitalized acute schizophrenics","volume":"18","author":"Kramer","year":"1975","journal-title":"Current Therapeutic Research"},{"key":"10.1002\/14651858.CD011655.pub2-BIB0003|cit2","first-page":"69","article-title":"Metiapine and chlorpromazine","volume":"9","author":"Simpson","year":"1973","journal-title":"Bulletin"},{"issue":"10","key":"10.1002\/14651858.CD011655.pub2-BIB0002|cit3","first-page":"408","article-title":"A controlled comparison of metiapine and chlorpromazine in chronic schizophrenia","volume":"13","author":"Simpson","year":"1973","journal-title":"Journal of Clinical Pharmacology"},{"issue":"10","key":"10.1002\/14651858.CD011655.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/j.1552-4604.1975.tb05923.x","article-title":"Metiapine: a double-blind comparison with chlorpromazine in acute schizophrenic patients","volume":"15","author":"Steinbook","year":"1975","journal-title":"Journal of Clinical Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD011655.pub2-BIB0005|cit5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000284.pub3","article-title":"Chlorpromazine versus placebo for schizophrenia","author":"Adams","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD011655.pub2-BIB0006|cit6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007445.pub2","article-title":"Chlorpromazine for psychosis induced aggression or agitation","author":"Ahmed","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD011655.pub2-BIB0007|cit7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006329","article-title":"Cessation of medication for people with schizophrenia already stable on chlorpromazine","author":"Almerie","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7066","key":"10.1002\/14651858.CD011655.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD011655.pub2-BIB0009|cit9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011662","article-title":"Acetophenazine versus chlorpromazine for schizophrenia","author":"Bazrafshan","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011655.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD011655.pub2-BIB0011|cit11","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"issue":"10","key":"10.1002\/14651858.CD011655.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Carpenter","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011655.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1192\/S0007125000071919","article-title":"Positive and negative schizophrenic symptoms and the role of dopamine","volume":"137","author":"Crow","year":"1980","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011655.pub2-BIB0014|cit14","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"key":"10.1002\/14651858.CD011655.pub2-BIB0015|cit15","unstructured":"Deeks JJ Higgins JPT Altman DG Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"7","key":"10.1002\/14651858.CD011655.pub2-BIB0016|cit16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010644","article-title":"Zotepine versus placebo for schizophrenia","author":"Dickenson","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD011655.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011655.pub2-BIB0018|cit18","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009831","article-title":"Haloperidol versus first generation antipsychotics for schizophrenia","author":"Dold","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011655.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD011655.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD011655.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD011655.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.cpr.2013.07.001","article-title":"Psychosocial treatments for negative symptoms in schizophrenia: current practices and future directions","volume":"33","author":"Elis","year":"2013","journal-title":"Clinical Psychology Review"},{"issue":"6","key":"10.1002\/14651858.CD011655.pub2-BIB0023|cit23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011709","article-title":"Chlorpromazine versus piperacetazine for schizophrenia","author":"Eslami Shahrbabaki","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD011655.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD011655.pub2-BIB0025|cit25","first-page":"794","article-title":"Metiapine: a new antipsychotic agent","volume":"12","author":"Gallant","year":"1970","journal-title":"Current Therapeutic Research"},{"issue":"2","key":"10.1002\/14651858.CD011655.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0041-008X(73)80008-0","article-title":"Toxicity studies with metiapine","volume":"25","author":"Gibson","year":"1973","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1002\/14651858.CD011655.pub2-BIB0027|cit27","first-page":"97","article-title":"The third revolution in psychiatry: fluphenazine decanoate","volume-title":"The Future of Pharmacotherapy: Drug Delivery System","author":"Grozier","year":"1973"},{"key":"10.1002\/14651858.CD011655.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD011655.pub2-BIB0029|cit29","doi-asserted-by":"crossref","unstructured":"Guy U Early Clinical Drug Evaluation (ECDEU) Assessment Manual for Psychopharmacology National Institute of Mental Health 1976","DOI":"10.1037\/e591322011-001"},{"key":"10.1002\/14651858.CD011655.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011655.pub2-BIB0031|cit31","unstructured":"Higgins JPT Green S Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD011655.pub2-BIB0032|cit32","unstructured":"Higgins JPT Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD011655.pub2-BIB0033|cit33","unstructured":"Higgins JPT Altman DG Sterne JAC Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD011655.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/1097-4679(196501)21:1<65::AID-JCLP2270210122>3.0.CO;2-I","article-title":"The nurses' observation scale for inpatient evaluation. A new scale for measuring improvement in chronic schizophrenia","volume":"21","author":"Honigfeld","year":"1965","journal-title":"Journal of Clinical Psychology"},{"issue":"1","key":"10.1002\/14651858.CD011655.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.2009.07707.x","article-title":"Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials","volume":"146","author":"Hutton","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD011655.pub2-BIB0036|cit36","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"key":"10.1002\/14651858.CD011655.pub2-BIB0037|cit37","first-page":"620","article-title":"Metiapine: neuroleptic and peripheral autonomic attributes","volume":"29","author":"Ketteler","year":"1970","journal-title":"Federation of American Societies for Experimental Biology"},{"issue":"8","key":"10.1002\/14651858.CD011655.pub2-BIB0038|cit38","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011831","article-title":"Chlorpromazine versus penfluridol for schizophrenia","author":"Khalili","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD011655.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","article-title":"Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology","volume":"59","author":"Leon","year":"2006","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD011655.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD011655.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD011655.pub2-BIB0042|cit42","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004278.pub2","article-title":"Haloperidol versus chlorpromazine for schizophrenia","author":"Leucht","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD011655.pub2-BIB0043|cit43","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007778","article-title":"Chlorpromazine dose for people with schizophrenia","author":"Liu","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011655.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD011655.pub2-BIB0045|cit45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011810","article-title":"Chlorpromazine versus clotiapine for schizophrenia","author":"Mazhari","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9263","key":"10.1002\/14651858.CD011655.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(00)04337-3","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"357","author":"Moher","year":"2001","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011655.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD011655.pub2-BIB0048|cit48","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"7","key":"10.1002\/14651858.CD011655.pub2-BIB0049|cit49","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010631","article-title":"Chlorpromazine versus atypical antipsychotic drugs for schizophrenia","author":"Saha","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011655.pub2-BIB0050|cit50","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD011655.pub2-BIB0051|cit51","unstructured":"Sterne JAC Egger M Moher D Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"8","key":"10.1002\/14651858.CD011655.pub2-BIB0052|cit52","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009227","article-title":"Flupenthixol versus low-potency first generation antipsychotic drugs for schizophrenia","author":"Tardy","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD011655.pub2-BIB0053|cit53","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009227.pub2","article-title":"Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia","author":"Tardy","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD011655.pub2-BIB0054|cit54","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009268.pub2","article-title":"Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia","author":"Tardy","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD011655.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jclinepi.2004.02.018","article-title":"Effect sizes in cumulative meta-analyses of mental health randomised trials evolved over time","volume":"57","author":"Trikalinos","year":"2004","journal-title":"Journal of Clinical Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD011655.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD011655.pub2-BIB0057|cit57","volume-title":"World Health Report","author":"World Health Organization","year":"2001"},{"key":"10.1002\/14651858.CD011655.pub2-BIB0058|cit58","volume-title":"WHO Model List of Essential Medicines","volume":"17","author":"World Health Organization","year":"2011"},{"issue":"7","key":"10.1002\/14651858.CD011655.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD011655.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T15:32:03Z","timestamp":1688916723000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011655.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,3,25]]},"references-count":59,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011655.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,25]]}}}